Combination therapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two experimental drugs (AK104 and AK112) combined with an oral tablet (TT-00420) for people with advanced hepatocellular carcinoma (a type of liver cancer) who have not had previous systemic treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced liver cancer (hepatocellular carcinoma) that cannot be treated with local therapies like surgery or ablation.
- You must have at least one measurable tumor (by imaging) that can be tracked over time.
- Your liver function must be well enough (Child-Pugh score of 7 or less) and you should be in good daily health (ECOG 0 or 1).
- If you have hepatitis B or C, it must be well controlled with medication.
- You must not have had any prior systemic cancer treatments for liver cancer (for specific groups).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of three drugs (TPST-1120, atezolizumab, and bevacizumab) for people with advanced liver cancer that hasn't been treated before. The goal is to see if adding this new drug to the standard immunotherapy and targeted therapy helps shrink or control the cancer better.
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
This trial tests a new drug called SH006 combined with another treatment against a standard drug (regorafenib) for advanced liver cancer. It is for people whose cancer has stopped responding to immunotherapy, and the goal is to see if it helps them live longer or shrinks the tumor.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.